1. Effect of tibolone on the survival of early stage cervical adenocarcinoma patients
- Author
-
Kyung-Joo Cho, Seungjoo Chon, Seungho Lee, Yoon-Jin Cho, Soyi Lim, Kwang-Beom Lee, Sun-Young Jung, and Mee-Hyang Ko
- Subjects
Oncology ,medicine.medical_specialty ,Population ,Tibolone ,survival ,lcsh:Gynecology and obstetrics ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,uterine cervical neoplasm ,Medicine ,Stage (cooking) ,Adverse effect ,education ,lcsh:RG1-991 ,education.field_of_study ,030219 obstetrics & reproductive medicine ,adenocarcinoma ,business.industry ,Medical record ,Hazard ratio ,Obstetrics and Gynecology ,medicine.disease ,Confidence interval ,tibolone ,030220 oncology & carcinogenesis ,Adenocarcinoma ,prognosis ,business ,medicine.drug - Abstract
Objective Gynecologic oncologists are uncertain about the safety of tibolone application in cervical adenocarcinoma (AC) patients. This study examined the possible adverse effects of tibolone on the survival of cervical AC patients. Methods Medical records of 70 cervical AC patients with International Federation of Gynecology and Obstetrics stages IA to IB were reviewed. A bilateral salpingo-oophorectomy was performed in all patients, and survival outcomes between tibolone users (n=38) and non-users (n=32) were compared. Results A comparison of the tibolone users with non-users revealed similar clinicopathological variables. Progression-free survival (P=0.34) and overall survival (P=0.22) were similar in the users and non-users. The risks of progression (hazard ratio [HR], 1.71; 95% confidence interval [CI], 0.46-6.37; P=0.43) and death (HR, 1.59; 95% CI, 0.06-45.66; P=0.79) were also similar in both groups. Conclusion Tibolone has no adverse effect on the survival of cervical AC patients and can be administered safely to this population. These findings may be helpful in improving the quality of life of cervical AC patients.
- Published
- 2018